Mark A. Wingertzahn

Dr. Mark Wingertzahn has over 25 years of experience in non-clinical and clinical development in Pharma, Biotech as well as the Consumer Healthcare areas. Mark is currently the Senior Vice President of R&D and Head of Development at Kaleido Biosciences where he is responsible for oversight and strategic direction of the global development teams. During his tenure at Kaledio, Mark has developed and executed clinical plans in rare disease, infectious disease, GI, Metabolic Health, and most recently for COVID-19.

Prior to Kaleido, Mark was Head of Clinical Development at GSK and prior to that was the Head of Global Clinical Research at Pfizer Consumer Health. In both roles, he provided strategic leadership and oversight of department operations for the global team responsible for clinical development activities and regulatory submissions across all therapeutic areas, including CNS/Pain, Respiratory, Medicinal foods, and Rx-to-OTC switch candidates in Sleep, Men’s Health, Cardiovascular, and smoking cessation that has yielded over 10 NDA’s and 3 first-in-class multi-national drug approvals including one Rx-to-OTC switch.